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vessel and to stent type (bare metal stent (BMS) or drug-eluting stent (DES)). The results
were adjusted for background, and procedural factors. The primary outcome variables
were mortality, restenosis and stent thrombosis (ST).
Results: 7840 patients treated for a single proximal stenosis were identified. DES was used
in 35.5% of patients. The use of DES as compared to BMS in the proximal LAD was
associated with a lower restenosis rate (HR 0.39 CI 0.27- 0.55), a lower mortality (HR 0.58 CI
0.41-0.82) and a non-significant reduction in ST (HR 0.48 CI 0.12-1.91) However, in the
proximal RCA and LCX, DES was not associated with a lower restenosis rate (HR 0.86 CI
0.50-1.48, HR 0.55 CI 0.19-1.61, respectively), or mortality (HR 1.48 CI 0.92-2.40, HR 0.80
CI 0.39-1.63, respectively). There was no difference in ST rate in the RCA (HR 1.24 CI
0.65-2.39). In the LCX there were too few ST events to allow meaningful evaluation.
Conclusions: In this study of 6 years of stent implantations indexed in a national PCI registry
with complete coverage and follow-up DES compared to BMS in the proximal LAD was
associated with a lower incidence of restenosis and mortality without added risk of stent
thrombosis. In contrast DES in proximal LCX and RCA was not associated with lower event
rates. Our retrospective data support a particular indication for DES in the proximal LAD.
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Background: The SYNTAX Score (SS) is a useful angiographic tool to manage patients
with multivessel coronary artery disease (CAD) requiring coronary revascularization.
Discrepancy in SS between cath-lab personnel has been published. However, the score
variability and impact in every type of lesion has not reported. Our purpose was to assess
interobserver variability and impact in SS within lesion characteristics.
Methods: We selected coronary angiograms with left main and/or three-vessel CAD
disease without previous revascularization. After completing the basic training available
at the official SS website, two interventional cardiologists (IC) calculated global (n98
patients, 413 lesions) as well as per lesion SS (in 209/413 lesions, 50.6%). We analysed
global variability (Kappa and Bland Altman), per-lesion inter-observer variability (per-
centage of agreement and Kappa) and impact (percentage of total error observed and
multivariable model if discrepancy between observers was  3 points per lesion).
Results: Global SS interobserver variability was acceptable: Kappa 0,70 (0,59 – 0,81).
Visual analysis through Bland Altman was good, without systematic errors. Mild
disagreement in the total lesions per patient were observed between both IC (difference
0.33 lesions, K value 0,76).Per-lesion discrepancy and impact concerning adverse
characteristic scoring is detailed in TableI. Disagreements 3 points per lesion analyzed
was observed in 21,1%. This discrepancy corresponded 61% of the global SS error.
Lesion
characteristics
Agreement
(%)
Kappa value
(IC 95%))
Discrepancy
score(points)
Global
Error (%)
Multivariate
analysis OR (IC
95%)
Segments
allocation
81,50% S/D 116 29,66751918 2,05 (1,48-2,83;
p0,001)
Segments
alloscation in
CTO
92,90% S/D 10 2,557544757 S/D
Heavy
calcificacion
73,20% 0,39 (0,26–0,52) 112 28,64450128 1,52 (0,61–3,82;
p0,35)
Bifurcations 92,00% 0,83 (0,75–0,91) 17 4,347826087 10,5 (2,18–50,6;
p0,003)
Medina
classification
85,70% 0,71 (0,53–0,88) 18 4,603580563 0,64 (0,14–2,84;
p0,56)
Angulation 
70‘
73,00% 0,45 (0,23–0,67) 28 7,16112532 0,98 (0,26–3,72;
p0,98)
Chronic total
occlution
98,60% 0,94 (0,87–1,00) 20 5,115089514 S/D
Blunt/Bridging 92,9%/
62,7%
S/D 16 4,092071611 S/D
Aorto-ostial 97,60% 0,85 (0,71–0,99) 5 1,278772379 4,11 (0,49
(34; p0,18)
Length (20
mm)
88,00% 0,61 (0,47 (0,74) 25 6,393861893 1,85 (0,59
(5,79; p0,28)
Severe
tortuosity
94,30% 0,42 (0,15 (0,69) 24 6,138107417 3,32 (0,80
(13,69; p0,09)
Thrombus 100,00% 1,00 (1,00 (1,00) 0 0 S/D
Conclusions: The interobserver correlation per lesion was good, except between severe
calcificacions. However, it did not generate systematic significant errors. Segments allocation
and bifurcations, generates significant errors that impact in global SS. Future image integration
and standard interpretation of complex lesion may help to reduce SS variability.
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Background: Early generation drug eluting stent (DES) overlap (OL) is associated with
impaired long-term clinical outcomes whereas the impact of OL with newer generation
DES is unknown. We sought to study the long-term clinical outcomes of patients with and
without OL of early and newer generation DES.
Methods: We analyzed the clinical outcomes of 3,133 patients included in a prospective,
registry of the unrestricted use of DES according to stent type (early generation sirolimus-
eluting stents [SES; N1,532] versus newer generation everolimus-eluting stents [EES;
N1,601]), and the presence or absence of OL and number of stents per vessel: 969 (30.9%)
patients with DES OL, 446 (14.2%) patients with multiple DES in a vessel without OL, and
1,718 (54.8%) patients with a single DES per vessel. The primary outcome was a composite
of death, myocardial infarction (MI), and target vessel revascularization (TVR).
Results: The primary endpoint was more common in patients with OL (25.1%) than in
patients with multiple DES without OL (20.8%, adj HR1.46, 95% CI 1.03-2.09) and
patients with a single DES (18.8%, adj HR1.74, 95% CI 1.34-2.25, p0.001) at 3 years,
driven largely by a higher risk of both MI and TVR. A stratified analysis by stent type
showed a higher risk of the primary outcome in SES treated patients with OL (28.7%)
compared to other SES groups (without OL: 22.6%, HR1.46, 95% CI 1.02-2.08; single
DES: 17.6%, HR1.73, 95% CI 1.34-2.23), but not between EES treated patients with
OL(22.3%) and other EES groups (without OL: 18.5%, HR1.24, 95% CI 0.83-1.85;
single DES: 20.4%, HR1.21, 95% CI 0.93-1.57).
Conclusions: DES OL is associated with impaired clinical outcomes during
long-term follow-up. Compared with early generation SES, newer generation EES
appear to overcome this limitation and provide similar clinical outcomes
irrespective of OL status.
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Background: Everolimus-eluting stents (EES) reduce target lesion revascularization
(TLR) compared to bare metal stents (BMS), but cost more. Whether the increased costs
of EES are offset by reductions in costs of adverse clinical outcomes compared to BMS
is uncertain.
Methods: Percutaneous coronary intervention with EES (n1,024) and BMS (n819)
were performed at a single center (Wake Forest Baptist Medical Center) between January
2007 and December 2010. One year clinical outcomes and costs in 2010 dollars were
prospectively evaluated and compared for propensity score matched patients. Follow-up
was 94% for both groups.
Results: Baseline characteristics were similar for matched EES and BMS (n714 for both).
Clopidogrel use at 1 year was 87% EES vs. 61% BMS (p0.001). Initial cost difference
between DES and BMS was almost entirely offset by lower repeat revascularization costs at
1 year (5.6/100 patients), with clopidogrel costs representing 97% of the remaining cost
difference. Aggregate 1-year costs were $456 more ($508 less to $1,291 more) with EES
(p0.32), yielding an incremental cost effectiveness ratio of $8,135 per TLR avoided with
EES. The cost effectiveness profile of EES was highly sensitive to cost of clopidogrel.
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Propensity score matched cumulative one year costs
Variable
EES BMS Difference p for
(N  714) (N  714) (95% CI) Difference
Index stenting
cost, $
2288 1104
[1,650]
1107528
[800]
1181
(1094 to 1274)
0.001
Follow-up costs
Repeat
revascularization
cost, $
917 7551
[0]
2086 9395
[0]
-1169
(-2105 to -344)
0.010
Clopidogrel
therapy cost, $
1939 562
[2139]
1496 862
[2139]
443
(367 to 511)
0.001
Aggregate 1-year
cost, $
5145 7612
[3789]
4689 9436
[2939]
456
(-508 to 1291)
0.32
Assuming
generic
clopidogrel cost,
$*
3537 7662
[2015]
3448 9429
[1165]
88
(-864 to 922)
0.85
Values in brackets are medians. *Cost of generic clopidogrel assumed as $1/day.
Conclusions: In this prospective observational registry, the cost per TLR avoided with
EES was $10,000. With the advent of generic thienopyridine availability, the cost
effectiveness profile shifts significantly in favor of EES, with similar 1-year aggregate
costs compared to BMS.
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Background: The efficacy and safety of XIENCE V® everolimus-eluting coro-
nary stents (XIENCE V, Abbott Vascular, Santa Clara, CA, USA) have been
demonstrated in pre-marketing and post-marketing studies with low rates of target
lesion revascularization (TLR), major cardiac adverse events and stent thrombosis
(ST). However, these results were mainly obtained in populations of European
heritage. SEEDS is the first study in China to evaluate XIENCE V’s performance
in Chinese patients with complex lesions.
Methods: This is a prospective, multicenter registry designed to enroll up to 1900
patients with long lesions or small vessel/multivessel coronary disease at 45 sites in
Mainland China, Taiwan and Macao. The primary endpoint is ischemia-driven target
vessel failure (TVF) at 12-month. Clinical follow-up is at 30 days, 6, 12 and 24 months.
All clinical endpoints are adjudicated by independent clinicians and 100% of data are
monitored. In this analysis, descriptive statistics are provided for baseline characteristics
and clinical endpoints by an independent statistical commission.
Results: A total of 365 (19.2%) small vessel patients, 781 (41.1%) long lesion patients,
and 754 (39.7%) multivessel patients with 2825 lesions were treated. Clinical, device and
lesion success rates were 99.47%, 99.95%, and 99.96% respectively. The table below
shows baseline characteristics and 30-day clinical outcomes.
Table: Baseline Characteristics and 30-Day Clinical Outcome
Baseline
Characteristics
(N1,900)
Age (years) 59.59 9.50
Diabetes 27.94%
Current smoker 42.42%
Hypertension 64.35%
Hyperlipidemia 37.33%
Prior MI 25.11%
% Pts with  2 Stents/Lesion 31.22%
Total stent length/lesion
(mm)
22.50 5.49
Clinical Endpoint Results at 30 Days
Small
Vessel
Long
Lesion
Multivessel
Disease All
(n365) (n781) (n754) (n1,900)
Death 0.00% 0.00% 0.27% 0.11%
Cardiac
death
0.00% 0.00% 0.27% 0.11%
MI 2.47% 2.56% 4.11% 3.16%
Q-wave MI 0.27% 0.38% 0.40% 0.37%
Non Q-wave
MI
2.19% 2.18% 3.71% 2.79%
TLR 0.0% 0.0% 0.27% 0.11%
TVF 2.47% 2.56% 4.77% 3.42%
Acute ST
(Def/Prob)
0.00% 0.26% 0.27% 0.21%
Subacute
ST(Def/
Prob)
0.55% 0.00% 0.40% 0.26%
Conclusions: In this large, multicenter, real-world study of Chinese population with
complex lesion subsets, XIENCE V demonstrated low rates of ST, TLR and TVF at
30-day. Long-term results will document the safety and effectiveness of XIENCE V in
high risk cohorts with long lesion and small vessel/multivessel disease from clinical
settings in China. 6-month results will be available at TCT Miami.
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Background: The SPIRIT PRIME trial demonstrated the clinical equivalence of the next
generation XIENCE PRIME everolimus-eluting stent (EES, Abbott Vascular, Santa
Clara, CA) to the XIENCE V EES at 1 year. Longer-term outcomes with the XIENCE
PRIME stent have not been investigated.
Methods: SPIRIT PRIME, a prospective, pivotal, non-randomized clinical trial with two
separate arms, tested the XIENCE PRIME in both core size (CSR) and long length (LLR)
(33 and 38 mm) stent registries. The CSR analyzed 401 patients and the LLR 104 patients.
Treatment of up to 2 de novo lesions in different epicardial vessels was allowed. The
primary endpoint was 1-year target lesion failure (TLF; cardiac death, target vessel
myocardial infarction [TV-MI] or clinically indicated target lesion revascularization
[CI-TLR]) compared to pre-specified performance goals based on historical data and in
accordance with FDA requirements. Data were fully monitored and all endpoint events
adjudicated by an independent clinical events committee.
Results: There were 447 target lesions treated in the CSR and 124 in the LLR. Clinical
device success rates were 98.2% in the CSR and 97.6% in the LLR. Female and diabetic
subjects were 29.7% and 34.9% in the CSR and 37.5% and 35.6%, in the LLR,
respectively. Elderly subjects (65 years old) comprised 41.6% of the CSR and 46.2% of
the LLR. The Table shows outcomes through 2 years.
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